Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.38 |
| ▸ | GGH | Q92820 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15757967 | 0.90 | POLB (0.50) | POLBKMT2ATDP1ANPEPERAP1 | |
| SCHEMBL3380506 | 0.78 | ANPEP (0.40) | TDP1ANPEPERAP1ERAP2LTA4H | |
| SCHEMBL29148867 | 0.76 | FOLH1 (0.45) | ALDH1A1TSHRGGH | |
| SCHEMBL28111320 | 0.75 | POLB (0.42) | POLBTDP1ALDH1A1TSHRANPEP | |
| SCHEMBL3380549 | 0.75 | S1PR2 (0.46) | TDP1TSHRANPEPERAP1ERAP2 | |
| SCHEMBL8732951 | 0.74 | NPSR1 (0.50) | POLBKMT2AALDH1A1TSHRLTA4H | |
| SCHEMBL3659563 | 0.73 | CA4 (0.37) | KMT2A | |
| SCHEMBL4751449 | 0.73 | CA4 (0.37) | KMT2A | |
| SCHEMBL8458374 | 0.72 | POLB (0.53) | POLBKMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4422382 | 0.72 | POLB (0.47) | POLBKMT2AALDH1A1TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193914-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016040179-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-3193914-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016040179-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2014085575-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-1443954-B1 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | SCRIPPS RESEARCH INST (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7399743-B2 | Targeted thrombosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1443954-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | Novartis Pharma GmbH (AT) | 2004-08-11 | — | — | EP | disclosed |
| US-20030194400-A1 | Targeted thrombosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-5863536-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITOR FOR THE TREATMENT OF GLUTAMATE ABNORMALITIES AND ASSOCIATED NERVOUS TISSUE ISCHEMIA IN A ANIMAL AND FOR TREATMENT OF PROSTATE DISEASE | GUILFORD PHARMACEUTICALS INC. (US) | 1999-01-26 | — | — | US | disclosed |